Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients

Annals of Oncology

Volumn 26, Issue 6, 2015, Pages 1238-1244

  Hecht, M ^a   Zimmer, L ^b   Loquai, C ^c   Weishaupt, C ^d   Gutzmer, R ^e   Schuster, B ^a   Gleisner, S ^a   Schulze, B ^f   M Goldinger, S ^g   Berking, C ^h   Forschner, A ⁱ   Clemens, P ^j   Grabenbauer, G ^k   Muller Brenne T ^c   Bauch, J ^d   Eich, H T ^d   Grabbe, S ^c   Schadendorf, D ^b   Schuler, G ^a   Keikavoussi, P ^a   Semrau, S ^a   Fietkau, R ^a   Distel, Luitpold ^a   Heinzerling, L ^a   more..

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j Hospital Feldkirch   (Austria)

^k KLINIKUM COBURG   (Germany)

more..

Author keywords

Braf; Dabrafenib; Radiation; Radiosensitization; Radiotherapy; Vemurafenib

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; FOTEMUSTINE; TEMOZOLOMIDE; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; RADIOSENSITIZING AGENT; SULFONAMIDE;

ADULT; AGED; ARTICLE; AUSTRIAN; BLOOD SAMPLING; BONE METASTASIS; BRAIN METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CHROMOSOME BREAKAGE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; FEASIBILITY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR CYSTIC PROLIFERATION; GERMAN (CITIZEN); HAND FOOT SYNDROME; HEARING DISORDER; HUMAN; HYPERPIGMENTATION; IONIZING RADIATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; MELANOMA; MULTICENTER STUDY; POLYNEUROPATHY; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIOSENSITIZATION; RETROSPECTIVE STUDY; SKIN CANCER; SKIN TOXICITY; SOFT TISSUE METASTASIS; STEREOTACTIC TREATMENT; TASTE DISORDER; VERY ELDERLY; WOUND HEALING IMPAIRMENT; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; ENZYMOLOGY; EUROPE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIATION TOLERANCE; RADIODERMATITIS; RADIOSURGERY; SKIN NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME; WHOLE BODY RADIATION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; EUROPE; FEASIBILITY STUDIES; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MIDDLE AGED; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIODERMATITIS; RADIOSURGERY; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 84938083571     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv139     Document Type: Article

References (28)

1. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
2. McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15:323-332.
3. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
4. Fonkem E, Uhlmann EJ, Floyd SR et al. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother 2012; 12: 1207-1215.
5. Anker CJ, Ribas A, Grossmann AH et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013; 31: e283-e287.
6. Merten R, Hecht M, Haderlein M et al. Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy. Strahlenther Onkol 2014; 190:1169-1172.
7. Peuvrel L, Ruellan AL, Thillays F et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 2013; 23: 879-881.
8. Satzger I, Degen A, Asper H et al. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol 2013; 31: e220-e222.
9. Schulze B, Meissner M, Wolter M, Rödel C, Weiss C. Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol 2014; 190:229-232.
10. Harding JJ, Barker CA, Carvajal RD et al. Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol 2014; 32: e54-e56.
11. Forschner A, Zips D, Schraml C et al. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 2014; 24: 512-516.
12. Reigneau M, Granel-Brocard F, Geoffrois L et al. Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis? Eur J Dermatol 2013; 23: 544-545.
13. Lang N, Sterzing F, Enk AH, Hassel JC. Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after wholebrain radiotherapy is a consequence of the development of multiple follicular cysts and milia. Strahlenther Onkol 2014; 190: 1080-1081.
14. Narayana A, Mathew M, Tam M et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013; 113: 411-416.
15. Rompoti N, Schilling B, Livingstone E et al. Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J Clin Oncol 2013; 31: 3844-3845.
16. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_Quick Reference:5x7.pdf (19 March 2015, date last accessed).
17. Keller U, Grabenbauer G, Kuechler A, Sauer R, Distel L. Technical report. Radiation sensitivity testing by fluorescence in-situ hybridization: how many metaphases have to be analysed? Int J Radiat Biol 2004; 80: 615-620.
18. Keller U, Grabenbauer G, Kuechler A et al. Cytogenetic instability in young patients with multiple primary cancers. Cancer Genet Cytogenet 2005; 157: 25-32.
19. Distel LV, Neubauer S, Keller U et al. Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. Radiother Oncol 2006; 81: 257-263.
20. Hauschild A, Grobb J, Demidov LV et al. An update on overall survival (OS) and follow-on therapies in BREAK-3, a phase III, randomized trial: dabrafenib (D) vs. dacarbazine (DTIC) in patients (pts) with BRAF V600E mutation-positive metastatic melanoma (MM). Ann Oncol 2014; 25: iv374-iv393.
21. Ridolfi L, de Rosa F, Ridolfi R et al. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. J Transl Med 2014; 12: 262.
22. Mattei PL, Alora-Palli MB, Kraft S et al. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol 2013; 24: 530-537.
23. Menzies AM, Kefford RF, Long GV. Paradoxical oncogenesis: are all BRAF inhibitors equal? Pigment Cell Melanoma Res 2013; 26: 611-615.
24. Dasgupta T, Haas-Kogan DA, Yang X et al. Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Invest New Drugs 2013; 31: 1136-1141.
25. Sambade MJ, Peters EC, Thomas NE et al. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of BRAF with PLX-4032. Radiother Oncol 2011; 98: 394-399.
26. Dummer R, Goldinger SM, Turtschi CP et al. Vemurafenib in patients with BRAF (V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014; 50: 611-621.
27. Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-1095.
28. Mornex F, Thomas L, Mohr P et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003; 13: 97-103.